The company took on the name Kuros Biosciences when Cytos Biotechnology merged with Kuros Biosurgery in January 2016.

Kuros has assembled a pipeline of clinical stage programs in various stages of development and amassed significant clinical and preclinical data in a number of indications and applications primarily in the areas of sealants and orthobiologics - biologics for bone repair.